Abstract #2 - Health Outcomes up to 3 Years and Post-exertional Malaise in Patients After Hospitalization for COVID-19: Results From a Multicenter Prospective Cohort Study (Co-flow)

2e Nederlandse Long COVID Dag 2025

#5 - Preliminary Safety, Efficacy, and Acceptability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Children and Infants From 1 Month Old Weighing 6–<14 KG - Carina Rodriguez

International Workshop on Pediatrics & HIV 2024

Finding the Missing Tuberculosis Cases: Lessons Learnt From Using Artificial Intelligence Enabled Chest X-Ray System for Active TB Case Search in Communities in Lagos, Nigeria

Conference on Innovations in Tuberculosis 2024

Seroprevalence and Correlates of Co-infection With HIV and Active Syphilis Among Women in Six Sub-Saharan African Countries: Results From Population-Based HIV Impact Assessments (PHIAs)

International Workshop on HIV & Women 2024

#8 - Predictors of Cognitive Decline Over 10 Years Among Older Adults With Well-Controlled HIV From the Positive Brain Health Now Cohort - Marie-Josée Brouillette

International Workshop on HIV & Aging 2023

Velpatasvir-Based Regimens in Treatment-Naïve and Treatment-Experienced Adults with Resistant Hepatitis C Virus Genotype 4 Subtypes Endemic to Sub-Saharan Africa: Findings from the SHARED-3 Study in Rwanda

Conference on Liver Disease in Africa (COLDA) 2021

APOBEC Editing in HIV DNA Proviral Vif and Pol Long-Reads Issued from Virologically-Suppressed Patients Included in the ANRS LAMIDOL Trial - Charlotte Charpentier, PharmD, PhD

European Meeting on HIV & Hepatitis 2021

For Each Hour a Patient Living with HIV Spends in the Health Facility, the Probability of Being Retained in Care Decreases: Results from a Patients’ Satisfaction Survey in Mozambique - Caroline De Schacht

INTEREST 2020

Peer-Led Community-Based Interventions Are Effective in Ensuring HIV-Positive Men Who Have Sex With Men and Transgender People Achieve Viral Suppression: Evidence From Malawi

INTEREST 2020

Twenty-Four Week Safety, Tolerability and Efficacy of Dolutegravir Dispersible Tablets in Children 4 Weeks to <6 Years Old with HIV: Results from IMPAACT P1093 - Theodore Ruel

International Workshop on HIV Pediatrics 2020